CVS Health Reports Mixed Q4 & Full-Year 2025 Results, Lowers 2026 Cash Flow Guidance Amid Significant Charges
CVS sits 43% above its 52-week low of $53.36.
Summary
CVS Health announced mixed Q4 and full-year 2025 results, featuring record revenues but a significant goodwill impairment and legacy litigation charges. The company also lowered its 2026 cash flow guidance, signaling potential future liquidity concerns.
Key Events · Earnings and Guidance · CVS
-
Full-Year 2025 Adjusted EPS Increased, GAAP EPS Declined
CVS Health reported full-year 2025 total revenues of $402.1 billion, up 7.8%, and Adjusted EPS of $6.75, up from $5.42 in the prior year. However, GAAP diluted EPS for the full year decreased significantly to $1.39 from $3.66, primarily due to non-recurring charges.
-
Significant Goodwill Impairment and Legacy Litigation Charges
The company recorded a $5.7 billion goodwill impairment charge related to its Health Care Delivery reporting unit and approximately $1.2 billion in legacy litigation charges during the full year 2025, materially impacting GAAP operating income and net income.
-
2026 Cash Flow Guidance Lowered
CVS Health updated its 2026 full-year cash flow from operations guidance to at least $9.0 billion, a reduction from its previous guidance of at least $10.0 billion.
-
Q4 2025 Adjusted EPS Decreased
For the fourth quarter of 2025, Adjusted EPS decreased to $1.09 from $1.19 in the prior year, primarily due to a decline in adjusted operating income in the Health Care Benefits segment, reflecting changes in Medicare Part D program seasonality.
Analysis · CVS · Trade & Services
CVS Health reported record full-year revenues and strong adjusted EPS growth for 2025. However, the report is significantly impacted by a substantial $5.7 billion goodwill impairment charge related to its Health Care Delivery unit and $1.2 billion in legacy litigation charges, which severely reduced GAAP diluted EPS for the full year. Furthermore, the company lowered its 2026 cash flow from operations guidance from at least $10.0 billion to at least $9.0 billion, indicating a weaker outlook for future liquidity. The Health Care Benefits segment also experienced an adjusted operating loss in Q4 2025 and a year-over-year decline in medical membership. These negative factors, particularly the large non-recurring charges and the reduced cash flow guidance, overshadow the positive revenue trends and adjusted earnings growth, suggesting underlying operational and legal challenges.
At the time of this filing, CVS was trading at $76.09 on NYSE in the Trade & Services sector, with a market capitalization of approximately $96.2B. The 52-week trading range was $53.36 to $85.15. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.